Azafaros Publishes Phase 2 RAINBOW Study Data for Nizubaglustat in GM2 Gangliosidosis and Niemann-Pick Type C Disease
Key Insights
The Phase 2 RAINBOW study met its primary objective, demonstrating that oral nizubaglustat was safe and well tolerated in patients with genetically confirmed GM2 gangliosidosis (search) and NPC.
Treatment with nizubaglustat showed encouraging signs of clinical efficacy, including reduced disease progression and seizure burden in the study population.
The peer-reviewed publication in Molecular Genetics & Metabolism supports two ongoing registrational Phase 3 studies evaluating nizubaglustat in GM1/GM2 gangliosidoses and NPC.
Azafaros (search) announced the publication of clinical data from its Phase 2 RAINBOW study in the peer-reviewed journal Molecular Genetics & Metabolism, marking an important milestone for the company and the broader lysosomal disease community. The published manuscript reports efficacy, safety, pharmacokinetic, and pharmacodynamic data evaluating nizubaglustat in patients with genetically confirmed GM2 gangliosidosis (search) and Niemann-Pick type C disease (search) (NPC).
The RAINBOW study met its primary objective of demonstrating that nizubaglustat was safe and well tolerated. The study also showed encouraging signs of clinical efficacy, reducing disease progression and seizure burden in patients treated with the investigational therapy.
"The publication of the RAINBOW data in a peer-reviewed journal represents an important milestone for Azafaros (search) and for the broader lysosomal disease community," said Stefano Portolano, Chief Executive Officer at Azafaros. "These data further support the therapeutic potential of nizubaglustat to address the neuronopathic symptoms in diseases where there is a strong unmet medical need and reinforce our confidence as we advance our two Phase 3 studies treating patients with GM1/GM2 gangliosidoses and NPC."
Professor Roberto Giugliani, Principal Investigator of the RAINBOW study, added: "The publication of the RAINBOW study results represents an important step in advancing the scientific understanding of nizubaglustat in GM2 gangliosidosis (search) and Niemann-Pick type C disease (search). The data support the safety profile observed in the study and provide encouraging evidence for continued clinical development in these devastating rare diseases."
Study Design and Key Findings
The RAINBOW study was a randomized, double-blind, placebo-controlled Phase II study evaluating the safety, tolerability, and pharmacological profile of oral nizubaglustat in patients with GM2 gangliosidosis (search) or Niemann-Pick type C disease (search). The study aimed to determine appropriate dosing and assess how the drug is processed and acts in the body. Following completion of the 12-week placebo-controlled phase, patients entered an ongoing extension phase in which all participants received nizubaglustat. Topline results from the study were initially announced in July 2024.
Nizubaglustat: Dual Mode of Action
Nizubaglustat is a small molecule, orally available and brain-penetrant azasugar with a unique dual mode of action, developed as a potential treatment for rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses and NPC. The compound has received Rare Pediatric Disease Designations for the treatment of GM1 and GM2 gangliosidoses and NPC, Orphan Drug Designations for GM1 and GM2 gangliosidosis (search) (Sandhoff and Tay-Sachs Diseases) and NPC, as well as Fast Track Designation and IND clearance for GM1/GM2 gangliosidoses and NPC from the US Food and Drug Administration (FDA). Additionally, nizubaglustat has been awarded Orphan Medicinal Product Designation for the treatment of GM1 and GM2 gangliosidoses by the European Medicines Agency (EMA) and Innovation Passport for the treatment of GM1 and GM2 gangliosidoses from the UK Medicines and Healthcare Products Regulatory Agency (MHRA).
Disease Background and Unmet Need
GM1 gangliosidosis (search) and GM2 gangliosidosis (search) (Tay-Sachs and Sandhoff diseases) are lysosomal storage disorders caused by the accumulation of GM1 or GM2 gangliosides, respectively, in the central nervous system (CNS). This results in progressive and severe neurological impairment and premature death. These diseases mostly affect infants and children, and no disease-modifying treatments are currently available.
Niemann-Pick type C disease (search) is a progressive, life-limiting, neurological lysosomal storage disorder caused by mutations in the NPC1 or NPC2 gene and aberrant endosomal-lysosomal trafficking, leading to the accumulation of various lipids, including gangliosides in the CNS. The onset of the disease can occur throughout the lifespan of an affected individual, from prenatal life through adulthood.
Advancing Toward Registration
The published data further support two ongoing registrational Phase 3 studies with nizubaglustat in GM1/GM2 gangliosidoses and NPC. Azafaros (search), a clinical-stage company founded in 2018 with compound discoveries made by scientists at Leiden University and Amsterdam UMC, is supported by leading healthcare investors including Forbion, Jeito Capital, Seroba, Pictet Group, BioGeneration Ventures (BGV), BioMedPartners, Asahi Kasei Pharma Ventures, and Schroders Capital.